Minimum Supersymmetric Standard Model on the Noncommutative Geometry

We have obtained the supersymmetric extension of spectral triple which specify a noncommutative geometry(NCG). We assume that the functional space H constitutes of wave functions of matter fields and their superpartners included in the minimum supersymmetric standard model(MSSM). We introduce the internal fluctuations to the Dirac operator on the manifold as well as on the finite space by elements of the algebra A in the triple. So, we obtain not only the vector supermultiplets which meditate SU(3)xSU(2)xU(1)_Y gauge degrees of freedom but also Higgs supermultiplets which appear in MSSM on the same standpoint. Accoding to the supersymmetric version of the spectral action principle, we calculate the square of the fluctuated total Dirac operator and verify that the Seeley-DeWitt coeffients give the correct action of MSSM. We also verify that the relation between coupling constants of $SU(3)$,$SU(2)$ and $U(1)_Y$ is same as that of SU(5) unification theory

Supersymmetric Yang-Mills Theory on the Noncommutative Geometry

Recently, we found the supersymmetric counterpart of the spectral triple. When we restrict the representation space to the fermionic functions of matter fields, the counterpart which we name "the triple" reduces to the original spectral triple which defines noncommutative geometry. We see that the fluctuation to the supersymmetric Dirac operator induced by algebra in the triple generates vector supermultiplet which mediates gauge interaction. Following the supersymmetric version of spectral action principle, we calculate the heat kernel expansion of the square of fluctuated Dirac operator and obtain the correct supersymmetric Yang-Mills action with U(N) gauge symmetry.Comment: arXiv admin note: text overlap with arXiv:1201.344

Adalimumab Dose-Escalation Therapy Is Effective in Refractory Crohn’s Disease Patients with Loss of Response to Adalimumab, Especially in Cases without Previous Infliximab Treatment

Background/Aims: Adalimumab dose escalation is one of the most important options in refractory Crohn’s disease patients with loss of response to adalimumab. The goal of this study was to evaluate the effectiveness of adalimumab dose escalation in Crohn’s disease patients with loss of response to adalimumab, since there are few reports of adalimumab dose escalation, especially in East Asia. Methods: The clinical response to adalimumab dose escalation in Crohn’s disease patients with loss of response to adalimumab was evaluated retrospectively, using the Crohn’s disease activity index score, serum C-reactive protein levels, and endoscopic analyses. Results: Of the 203 Crohn’s disease patients treated with anti-tumor necrosis factor, 14 refractory Crohn’s disease patients with loss of response to adalimumab received adalimumab dose-escalation therapy. The C-reactive protein level was significantly reduced from the start to weeks 12 and 52 of adalimumab dose escalation in the whole group, although there were no significant reductions of Crohn’s disease activity index scores. Both Crohn’s disease activity index scores and C-reactive protein levels were significantly reduced from the start to weeks 12 and 52 of adalimumab dose escalation in patients without previous infliximab treatment, although C-reactive protein levels were positive in all cases with previous infliximab exposure at weeks 12 and 52. Endoscopic mucosal healing was achieved with adalimumab dose escalation in 2 cases without previous infliximab treatment. Conclusions: Adalimumab dose-escalation therapy is effective in refractory Crohn’s disease patients with loss of response to adalimumab, especially in cases without previous infliximab treatment

Left atrial extension of metastatic lung tumor via pulmonary vein: report on the first case of Ewing sarcoma

Extension of metastatic lung tumors into the left atrium via pulmonary veins is rare. Here, we report the first case of Ewing sarcoma exhibiting such extension. A 31-year-old man with pulmonary metastasis from Ewing sarcoma presented with a mass in the left lung, extending to the left atrium through the left inferior pulmonary vein. As the patient was considered to be at risk of tumor embolism, the mass was excised surgically